Biotech | May 12, 2022
First patient dosed with antiepileptic drug candidate CB03 in a first-in-human Phase I trial
CB03 is a candidate drug for the treatment of refractory epilepsy, independently developed by Zhimeng
CB03 is a candidate drug for the treatment of refractory epilepsy, independently developed by Zhimeng
The funding will enable the company to expand into the segment of HealthCare Service offerings, both in terms of geography and operations
Company's net income rose by 57.5 percent to 3.291 billion euros in Q1
Evonik in association with Remondis has opened its first plant in India to ensure Zero Liquid Discharge. It is located at Dombivli in Western Maharashtra
An Integrated programme comprising GOQii device, Glucometer – Contour Plus+1 from Ascensia Diabetes Care India and personalised diabetes coaching
The announcement follows FDA 510(k) clearance of device
As an industrial partner of the IHU, the Medi-Globe Group is thus further expanding its role as an innovation leader in minimally invasive diagnostics and therapies
Approval based on groundbreaking Phase 3 EXPLORER-HCM trial demonstrating benefit in patients receiving Camzyos versus placebo
This action makes Veklury the first approved Covid-19 treatment for children less than 12 years of age
The innovative Fixed-Dose Combination will help improving the glycemic control among adult patients with insulin resistance, those whose diabetes is uncontrolled by metformin; and also those who require addition of Teneliglitptin and Pioglitazone as separate drugs.
Subscribe To Our Newsletter & Stay Updated
